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Abstract There appears to be a paucity of data examining the
effect of dietary antioxidants on levels of oxidative DNA damage
in vivo, limiting evidence-based assessment of antioxidant
efficacy, mechanisms and recommendation for optimal intake.
We have examined levels of 8-oxo-2P-deoxyguanosine (8-oxodG)
in mononuclear cell DNA, serum and urine from subjects
undergoing supplementation with 500 mg/day vitamin C.
Significant decreases in DNA levels of 8-oxodG were seen,
correlating strongly with increases in plasma vitamin C
concentration. Furthermore we established a timecourse for
sequential, significant increases in serum and urinary 8-oxodG
levels. These results illustrate, for the first time in humans, the
kinetics of 8-oxodG removal and processing in vivo, suggesting a
role for vitamin C in the regulation of DNA repair enzymes and
thereby demonstrating a non-scavenging antioxidant effect.
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1. Introduction
The e¡ect of speci¢c dietary antioxidants, such as vitamin
C, vitamin E and carotenoids, on oxidative DNA damage has
been di⁄cult to ascertain by epidemiological studies following
supplementation with fruit and vegetables [1]. It may be ex-
pected that such antioxidants would reduce the levels of oxi-
dative DNA damage. However, there appears to be limited in
vivo support for this hypothesis as a number of studies have
shown no such e¡ect following dietary supplementation with
vitamins C, E or carotenoids [2^5]. Most of these studies
measured urinary levels of 8-oxo-2P-deoxyguanosine (8-ox-
odG) as a marker and possible repair product of oxidative
DNA damage, facilitating the non-invasive monitoring of in
vivo oxidative stress [6^9]. 8-oxodG is understood to be a
mutagenic lesion in vivo, giving rise to GCT transversions
[10], and its successful repair is therefore essential. In mam-
malian cells, it would appear that 8-oxodG may be removed/
excluded from DNA by a number of processes including: a
glycosylase/apurinic lyase, hOgg1 [11,12] ; an 8-oxoG endonu-
clease [13] and thirdly, the human MutT homologue
(hMTH1) [14,15]. The latter two processes give rise to dam-
aged deoxynucleotides which may subsequently be enzymati-
cally hydrolysed to stable, water-soluble deoxynucleosides and
¢nally excreted in the urine.
We have recently noted an apparent antioxidant e¡ect in
vivo for vitamin C upon DNA in peripheral blood mononu-
clear cells (PBMC), as measured by GC-MS [16]. A reduction
in the levels of 8-oxoG was noted following supplementation
which may be expected to be re£ected in the urinary levels of
8-oxodG. Therefore, in this study, we have examined the ef-
fect of vitamin C supplementation upon the levels of 8-oxodG
excreted in the urine of subjects collected from our previous
trial [16]. We also report further HPLC-EC measurements of
both 8-oxoG and 8-oxodG in the DNA of mononuclear cells
collected previously and their correlation with plasma vitamin
C concentration.
2. Materials and methods
2.1. Supplementation protocol
Ethical approval for the study was given by the Leicestershire Area
Health Authority Ethics Committee and 30 healthy volunteer subjects,
consisting of 16 females and 14 males, were subsequently recruited.
The age of the subjects ranged from 17 to 49 and all gave written,
informed consent. Smokers, people taking vitamin supplements and/
or salicylates were excluded from the study. Fasting blood and ¢rst
morning urine samples were collected from all subjects to establish
baseline values. A 6-week placebo course (calcium carbonate: 500 mg/
day, orally) preceded a 6-week course of vitamin C (ascorbic acid: 500
mg/day, orally). Fasting blood and ¢rst morning urine samples were
taken at 3-weekly intervals up to 12 weeks and then at week 19. A
further urine sample was taken at week 25. At each collection, plasma
ascorbate levels were determined, PBMC-derived DNA extracted and
urinary creatinine levels measured.
2.2. Measurement of plasma vitamin C by HPLC
All chemicals were of the highest purity and unless stated otherwise,
were obtained from Sigma Chemical Co. (Poole, UK). The method
for analysis of plasma vitamin C was based upon that of Lunec and
Blake [17].
2.3. Isolation of PBMC
PBMC were isolated by double density centrifugation. Brie£y,
whole blood, diluted with an equal volume of PBS, was added to
two layers of Histopaque 1077 and 1119. Centrifugation at 700Ug,
18‡C for 30 min produced separation into ¢ve layers. Removal of the
uppermost plasma/platelet layer allowed collection of the second
(mononuclear cell) layer.
2.4. Extraction of PBMC DNA
This was performed essentially as described by Finnegan et al. [18],
with the following modi¢cations. RNA was digested with 20 Kunitz
units RNase A (EC 3.1.27.5 from bovine pancreas) in bu¡er (10 mM
Tris-HCl, 10 mM EDTA, 10 mM NaCl, pH 6.0) at 37‡C for 1 h, prior
to treatment with 3 units Pronase E (EC 3.4.24.31, protease from
Streptomyces griseus) at 37‡C, overnight. Following precipitation,
washing in ethanol and removal of excess ethanol under a gentle
nitrogen stream, DNA was dissolved in ultrapure water prior to quan-
titation by UV absorbance at 260 nm. Samples were divided into
aliquots and stored at 380‡C, if necessary, prior to digestion and
analysis.
2.5. Formic acid digestion of DNA and HPLC-EC of 8-oxoG
To an aliquot of DNA (20 Wg) in water, was added 16 nmol of
8-oxo-2,6-diaminopurine (8-oxoDAP; internal standard [19]). Samples
were hydrolysed with 60% v/v formic acid in sealed, evacuated hydrol-
ysis tubes at 140‡C for 30 min. The hydrolysate was freeze-dried then
reconstituted in ultrapure water and divided into two equal aliquots.
Each aliquot was adjusted to pH 8.0^8.5 with 0.1 M NaOH; one
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aliquot was treated with 0.85 mU guanase/10 Wg DNA (EC 3.5.4.3,
from rabbit liver) and the other with an equal volume of water at
37‡C for 1 h [20]. Reversed-phase HPLC-EC was used to analyse
8-oxoG and guanine as reported by Herbert et al. [20]. Quantitation
of 8-oxoG was achieved by plotting a standard curve of peak area
ratio, 8-oxoG:8oxoDAP, against 8-oxoG concentration; guanine was
quantitated by external calibration.
2.6. Enzymic digestion of DNA and HPLC-EC of 8-oxodG
Aliquots of DNA equivalent to 50^70 Wg were freeze-dried and
reconstituted in 20 mM sodium acetate, pH 4.8, containing 45 mM
zinc chloride. Samples were heated in a boiling water bath for 3 min
and cooled quickly on ice prior to the addition of nuclease P1 (EC
3.1.30.1, nuclease from Penicillium citrinum ; Calbiochem-Novabio-
chem, Nottingham, UK) to give 0.1 U/Wg DNA and incubation of
the samples at 37‡C for 1 h. Samples were made alkaline by the
addition of 1.5 M Tris-HCl, pH 8.0 and alkaline phosphatase (from
bovine intestine; EC 3.1.3.1; Boehringer-Mannheim, Lewes, UK)
added to give 0.05^0.075 U/Wg DNA and incubated at 37‡C for
0.5 h. Analysis of digests was performed by HPLC-EC as noted above
for 8-oxoG, using the same detection parameters UV254nm for 2P-de-
oxyguanosine and EC600mV for 8-oxodG; the mobile phase contained
10% v/v methanol. Quantitation was performed by external calibra-
tion using standards processed through exactly the same enzymic
digestion procedure as the samples.
2.7. Analysis of serum 8-oxodG
Samples of whole blood were allowed to coagulate prior to centri-
fugation (1500Ug for 15 min at 10‡C). Serum was collected and
stored at 380‡C, until analysis. Following thawing the supernatants
were applied to the competitive ELISA plate according to the proto-
col (8-OHdG check. Genox Corp., Baltimore, MD, USA) [21]. Quan-
titation was performed by external calibration using 8-oxodG stand-
ards.
2.8. Urinalysis
Collected urine samples from subjects were stored, without any
additives, at 380‡C in 20 ml plastic Universal tubes, until analysis.
Previous studies have shown 8-oxodG to be stable in urine for at least
1 year, following freezing [3]. Following thawing and centrifugation
(300Ug for 10 min), the supernatants were applied to the competitive
ELISA plate according to the protocol. In order to provide a internal
reference for urine concentration, aliquots of urine supernatant were
also assayed for creatinine (Department of Chemical Pathology, Lei-
cester Royal In¢rmary, Leicester, UK).
2.9. Statistical analyses
Data were analysed by the general linear model analysis of variance
with subsequent comparison between means using Fisher’s least sig-
ni¢cance di¡erence test. Analyses were performed using Minitab, ver-
sion 6.1 and GraphPad Prism, version 2.01.
3. Results
Supplementation of the subjects with 500 mg/day vitamin C
resulted in a highly signi¢cant increase (P6 0.001) in plasma
vitamin C compared to baseline and placebo timepoints, be-
fore returning to baseline after a 7-week washout period (Fig.
1). No signi¢cant di¡erence was observed between placebo,
baseline and washout values. Mean levels of 8-oxoG and
8-oxodG in PBMC DNA, as measured by HPLC-EC, showed
a signi¢cant decrease (P6 0.05) from baseline and placebo,
following 3 and 6 weeks of vitamin C supplementation (weeks
9 and 12, respectively). Following a 7-week washout period,
levels of 8-oxoG then increased to a level not signi¢cantly
di¡erent from those seen for baseline and placebo. Compar-
ison of all 8-oxodG measurements in DNA, obtained
throughout the vitamin C trial, with plasma vitamin C levels
showed there to be a highly signi¢cant negative correlation
(Table 1).
No signi¢cant variation in serum 8-oxodG, as determined
by competitive ELISA, was seen at the baseline, placebo or
week 9 (3 weeks of vitamin C supplementation) timepoints
(Fig. 2). A very signi¢cant (P6 0.001) increase in serum
8-oxodG was measured following 6 weeks of vitamin C sup-
plementation (week 12), which remained signi¢cantly elevated
(P6 0.001) at the ¢rst washout timepoint (week 19). Further
sampling 6 weeks later (week 25) showed that serum 8-oxodG
concentration had returned to a level comparable with base-
line. Analysis of serum 8-oxodG values showed a signi¢cant
positive correlation with plasma vitamin C concentration
(Table 1).
Levels of urinary 8-oxodG were also quantitated by com-
petitive ELISA and expressed relative to pmol of creatinine to
eliminate variations in urine concentration (Fig. 3). The mean
values of urinary 8-oxodG levels suggested an upward trend
from week 12, reaching statistical signi¢cance (P6 0.05) at
week 19, compared to the baseline and placebo values (Fig.
3). No statistically signi¢cant increase was seen during the
vitamin C supplementation phase, at either week 9 or week
12. Likewise, no signi¢cant changes were observed during the
baseline or placebo phases of the trial. Urine samples, pro-
vided by subjects at week 25, showed a decrease from the
values seen at week 19. No signi¢cant correlation with plasma
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Fig. 1. Representation of in vivo 8-oxodG kinetics in cellular com-
partments (DNA, serum and urine) and comparison with plasma vi-
tamin C levels. Data are expressed in terms of mean percentage var-
iation from baseline (100%). Asterisks indicate a signi¢cant
(*P6 0.05 and ***P6 0.001) di¡erence from baseline and placebo
measurements.
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vitamin C levels was seen. With the exception of week 9,
which showed a signi¢cant decrease, urinary levels of creati-
nine remained constant throughout the trial. Both intra- and
inter-assay variability of the competitive ELISA analysis of
serum and urine were shown to be 6 10%. The coe⁄cient
of variation of a routinely measured quality control standard
for the ELISA assay was also 6 10%.
4. Discussion
We have examined the e¡ect of dietary supplementation
with vitamin C on DNA levels of 8-oxoG, measured either
as the base or as the deoxynucleoside, along with serum and
urinary levels of 8-oxodG. Urinary 8-oxodG is considered a
biomarker for the rate of oxidative damage to DNA [22,23],
with elevated levels of urinary oxodG and, by implication,
DNA damage having been noted in individuals with malig-
nant disease compared with healthy controls [24^26]. Such
¢ndings further support urinary 8-oxodG output to be re£ec-
tive of in vivo oxidative stress. Our study is the ¢rst report
examining the e¡ect of vitamin C supplementation upon both
serum and urinary levels of 8-oxodG in normal, healthy in-
dividuals. There also appears to be no literature precedent for
the measurement of serum 8-oxodG, which was facilitated,
without enrichment, by the use of competitive ELISA. Com-
parison of our basal urinary 8-oxodG values with those de-
rived from HPLC-based methodology reveal that higher levels
are detected using the ELISA kit. Explanation for this is
based on our experimental evidence that the antibody has
the potential to bind 8-oxodG-containing oligonucleotides
(unpublished results) and 8-oxoguanosine [27], both putative
urinary competitors of the monoclonal antibody [28,29] and,
we propose, pertinent markers of oxidative stress. Full char-
acterisation of the monoclonal antibody used and its speci¢c-
ity for 8-oxodG has been reported by Toyokuni et al. [27].
Although there is evidence to suggest that dietary vitamin C
insu⁄ciency may give rise to increased levels of oxidative
DNA damage in vivo [30], there have been few reports of
clinical trials which support this hypothesis. Indeed, Duthie
et al. [31], whilst showing a reduction in oxidative DNA dam-
age upon supplementation with a mixture of antioxidants,
suggested that vitamin C was not responsible for this e¡ect.
This ¢nding would appear to be supported by Daube et al.
[32] who showed no association between plasma vitamin C
concentration and placental 8-oxodG levels. In contrast, we
have recently shown that dietary supplementation with vita-
min C reduces 8-oxoG levels in the DNA of circulating
PBMC [16]. The potential for vitamin C to exert such an
e¡ect is supported by Fraga et al. [30]. However, the apparent
antioxidant e¡ect, seen previously in PBMC [16], occurred
simultaneously with a pro-oxidant e¡ect, evident from an in-
crease in 8-oxoadenine (8-oxoA) levels. Analysis of the results
for DNA levels of 8-oxodG and 8-oxoG, described here,
showed highly signi¢cant negative correlations with plasma
vitamin C levels. These ¢ndings further support the strong
negative correlation between 8-oxoG and plasma vitamin C,
along with a positive correlation for 8-oxoA [33].
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Fig. 2. Levels of 8-oxodG, determined by competitive ELISA
(8-OHdG check, Genox Corp., Baltimore, MD, USA [21]), in serum
from subjects undergoing vitamin C supplementation. Values repre-
sent the mean and standard deviation for each sampling timepoint.
Fig. 3. Levels of 8-oxodG, determined by competitive ELISA
(8-OHdG check, Genox Corp., Baltimore, MD, USA [21]), in urine
from subjects undergoing vitamin C supplementation. Values repre-
sent the mean and standard deviation for each sampling timepoint.
Table 1
Correlation analysis data between plasma vitamin C levels, oxidative DNA damage, serum and plasma 8-oxodG levels
Analysis parameter Oxidative DNA lesion/method of analysis
8-oxoA
(GC-MS)
8-oxoG
(GC-MS)
8-oxoG
(HPLC-EC)
8-oxodG
(HPLC-EC)
Serum 8-oxodG
(ELISA)
Urinary 8-oxodG
(ELISA)
Pearson r 0.42 30.40 30.38 30.25 0.20 0.09
P value 6 0.0001 6 0.0001 6 0.0001 6 0.04 6 0.04 = 0.34
P value summary *** *** *** * * ns
Signi¢cant correlation with plasma vitamin C? Yes Yes Yes Yes Yes No
DNA levels of damage were measured by either GC-MS or HPLC-EC; serum and urinary 8-oxodG were determined by ELISA. Statistical analyses
were performed using Minitab, version 6.1 and GraphPad Prism, version 2.01.
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Loft et al. [3] report that the intake of vitamin C is not
associated with urinary 8-oxodG excretion. These results ap-
pear to contrast with our ¢ndings, which show that following
6 weeks of vitamin C supplementation (week 12), levels of
urinary 8-oxodG have begun to rise and become signi¢cantly
raised by week 19 (washout), 7 weeks following cessation of
supplementation. This occurs whilst levels of 8-oxoG in the
DNA of PBMC decrease during supplementation and return
to basal levels at washout. The discrepancy between our result
for urinary 8-oxodG and that described by Loft et al. [3] may
be explained by dose. We supplemented our subjects with
vitamin doses of 500 mg/day, compared to an average intake
of 72 mg/day used by Loft et al. [3]. We have previously
shown 500 mg/day to increase mean plasma vitamin C levels
by 60%, compared to baseline [16], suggesting that 500 mg/
day is more likely to be e¡ective at increasing plasma vitamin
C levels. An alternative explanation for the discrepancy may
come from a recent study by PriemeŁ et al. [4]. This study
showed a 10.2% increase in 8-oxodG excretion following sup-
plementation with 250 mg ascorbate (twice daily for 2 months)
which did not achieve statistical signi¢cance. In agreement
with this, we also note a non-signi¢cant, 21.9% increase
following 500 mg/day for 6 weeks. However, in contrast to
the study by PriemeŁ et al. [4], we continued to collect and
assay urine many weeks after cessation of vitamin C and
subsequently noted a signi¢cant 30.0% increase in urinary
8-oxodG, 7 weeks post cessation of vitamin C. Clearly it is
important to maintain sampling, even when plasma vitamin C
levels have returned to baseline. Examination of serum
8-oxodG levels show a similar trend to that seen in the urine,
only achieving signi¢cance 3 weeks in advance of the urine. It
is likely that this time delay between appearing in serum and
urine is re£ective of the in vivo kinetics of 8-oxodG distribu-
tion between these two compartments, a facet of 8-oxodG
processing previously unaddressed. The delay would also ex-
plain the lack of correlation between urinary 8-oxodG and
plasma vitamin C, as the changes seen were completely out
of phase.
First examination of the mean results for 8-oxodG in DNA
suggests that vitamin C is acting as an antioxidant by scav-
enging potentially damaging oxygen free radicals and prevent-
ing the formation of 8-oxoG, whilst steady-state DNA repair
removes existing lesions. However, there would appear to be
limited experimental evidence for vitamin C acting as a free
radical scavenger in vivo, with most evidence for this property
coming from in vitro studies [34]. Nevertheless, on the basis
that vitamin C does act as an antioxidant one would expect
serum and urinary levels of 8-oxodG derived from DNA and
other possible cellular sources of 8-oxodG to decrease. Instead
an increase is seen, suggesting an apparent pro-oxidant e¡ect
upon deoxyguanosine moieties, similar to that previously
noted for adenine in DNA [16]. There are a number of pos-
sible sources for 8-oxodG in the urine, regulated by enzymic
processes [13^15,29]. In consideration of this, several explan-
ations may account for the increase in serum and urinary
8-oxodG. Firstly, ascorbate may be acting as a pro-oxidant
for guanine moieties not contained in DNA, e.g. dGTP, giv-
ing rise to 8-oxodGTP which can be processed to 8-oxodG
and excreted [35]. Secondly, ascorbate may promote the ‘purg-
ing’ of 8-oxodG, derived from dGTP and/or DNA, from the
cellular environment. In both cases, this would suggest that
vitamin C is having some form of residual e¡ect, detectable
long after plasma values have returned to baseline, and that it
is the processing of these lesions which explains the delay
between their removal and appearance in the urine.
Another explanation may be that vitamin C is not acting as
an antioxidant per se but promotes the removal of 8-oxodG
from the DNA and/or nucleotide pool, via the upregulation of
repair enzymes, previously postulated by Rehman et al. [36],
perhaps induced by vitamin C’s pro-oxidant properties. There
is a precedent for the redox regulation of DNA repair en-
zymes [37], inclusion of which into our hypothesis and
coupled with a concomitant pro-oxidant e¡ect may present
some explanation for the decrease in DNA levels of
8-oxoG/8-oxodG reported here and previously [16] whilst se-
rum/urine levels of 8-oxodG increase. The increase in 8-oxoA
[16] may be explained if repair of this lesion had not been
stimulated. Indeed, recent work has shown that 8-oxoA, fol-
lowing its in situ formation rather than by mis-incorporation
into DNA, is a poor substrate for yOgg1, the yeast homo-
logue of the human hOgg1 enzyme [38]. The latter scenario is
best supported by current literature and o¡ers the most rea-
sonable explanation for the observed experimental events.
In conclusion, this study shows that vitamin C supplemen-
tation has signi¢cant in£uence upon DNA, serum and urinary
8-oxodG levels in vivo and has promoted the hypothesis that
vitamin C, perhaps through its redox properties [16], stimu-
lates the repair of 8-oxodG in DNA/nucleotide pool.
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